Devices and methods for treating tissue

• US 20040186587A1
• Filed: 01/28/2004
• Published: 09/23/2004
• Est. Priority Date: 06/09/1999
• Status: Abandoned Application

• Current Assignee: C.R. Bard, Inc. (Becton, Dickinson & Co)
• Original Assignee: C.R. Bard, Inc. (Becton, Dickinson & Co)
• Inventors: Ahern, John E.
• Application Number:
  US10/766,173
• Publication Number:
  US 20040186587A1
• Time in Patent Office: Days
• US Class Current: 623/23.71
• CPC Class Codes: A61B 17/00234 for minimally invasive surgery A61B17/0218, A61B17/0469, A61B17/12013, A61B17/1285, A61B17/29, A61B17/320016 take precedence
• CPC Class Codes: A61B 2017/00004 (bio)absorbable, (bio)resorbable, resorptive for implantable prostheses A61F2210/0004
• CPC Class Codes: A61B 2017/00247 Making holes in the wall of the heart, e.g. laser Myocardial revascularization
• CPC Class Codes: A61B 2017/00575 for closure at remote site, e.g. closing atrial septum defects
• CPC Class Codes: A61B 2017/00893 pharmaceutically effective
• CPC Class Codes: A61B 2017/1205 Introduction devices
• CPC Class Codes: A61B 2018/00392 Transmyocardial revascularisation
• CPC Class Codes: A61F 2/02 Prostheses implantable into the body closure means for urethra or rectum or for artificial body openings therefor A61F2/0004
• CPC Class Codes: A61F 2/2493 Transmyocardial revascularisation [TMR] devices
• CPC Class Codes: A61F 2/88 the wire-like elements formed as helical or spiral coils forming a net-like or mesh-like structure A61F2/90
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

The present invention provides devices and methods for treating biological tissue. The treatment comprise implanting a scaffold implant device into in combination with a therapeutic material such as cells, tissue or cell components. The scaffold device serves to hold the therapeutic material at the treatment site, protecting it from being squeezed out by surrounding tissue. Additionally the scaffold device is believed to trigger an injury response that leads to angiogenesis in the tissue, which provides blood flow and nutrients to the associated therapeutic material to sustain it for a therapeutically effective amount of time. The devices may also be implanted at a tissue site already treated with a therapeutic material to initiate angiogenesis at the treatment site to sustain the material. The devices and methods also may be used to treat tumors with a necrosis factor.

Claims

1. An implant for treating biological tissue comprising:

therapeutic material associated with a scaffold structure that is implantable within tissue.

2. A tissue implant as defined in claim 1 wherein the scaffold further comprises an interior defining a chamber and at least one opening to the interior, wherein the therapeutic material is associated with the interior of the scaffold.

3. A tissue implant as defined in claim 1 wherein the scaffold defines an exterior surface and the therapeutic material is associated with the exterior surface.

4. A tissue implant as defined in claim 1 wherein the scaffold structure is porous and a therapeutic material is associated within the pores of the structure.

5. A tissue implant as defined in claim 1 wherein the therapeutic material defines a plurality of cells.

6. A tissue implant as defined in claim 1 wherein the therapeutic material defines tissue.

7. A tissue implant as defined in claim 1 wherein the therapeutic material comprises precursor cells.

8. A tissue implant as defined in claim 1 wherein the therapeutic material comprises stem cells.

9. A tissue implant as defined in claim 1 wherein the therapeutic material comprises a cardiomyocyte.

10. A tissue implant as defined in claim 1 wherein the therapeutic material comprises DNA.

11. A tissue implant as defined in claim 1 wherein the therapeutic material comprises skeletal myoblasts.

12. A tissue implant as defined in claim 1 wherein the therapeutic material is joined to the scaffold structure by surgical adhesive.

13. A tissue implant as defined in claim 1 wherein the therapeutic material is applied as a coating to the scaffold structure.

14. A tissue implant as defined in claim 12 wherein the coating is adhered to the scaffold structure by opposite electrical charges.

15. A tissue implant as defined in claim 1 wherein the therapeutic material is maintained in a gel form that is associated with the scaffold.

16. A tissue implant as defined in claim 1 wherein the therapeutic material is suspended in a liquid that is applied to the scaffold after it has been implanted in tissue.

17. A tissue implant as defined in claim 1 wherein the scaffold further comprises a coil body.

18. A tissue implant device as defined in claim 1 wherein the scaffold further comprises a mesh tube

19. A tissue implant as defined in claim 1 wherein the scaffold structure further comprises a porous pellet.

20. A tissue implant as defined in claim 1 wherein the scaffold structure comprises a surgical grade stainless steel.

21. A tissue implant as defined in claim 1 wherein the scaffold structure comprises a nickel titanium alloy.

22. A tissue implant as defined in claim 1 wherein the scaffold structure comprises a biodegradable polymer.

23. A myocardial implant comprising:

an angiogenic implant device having associated with it a therapeutic material configured to improve cardiac muscle function.

24. A method of treating dysfunctional muscle tissue comprising:

providing therapeutic material configured to improve muscular function;

providing a angiogenic implant;

associating the therapeutic material with the angiogenic implant; and

implanting the angiogenic implant and therapeutic material in combination in dysfunctional tissue

25. A method of treating dysfunctional muscle tissue as defined in claim 24 wherein the muscle tissue is myocardial tissue of the heart.

26. A method of treating dysfunctional muscle tissue as defined in claim 25 wherein the heart is accessed surgically and the implant is delivered through the epicardium of the heart.

27. A method of treating dysfunctional muscle tissue as defined in claim 25 wherein the heart is accessed percutaneously and the implant is delivered through the endocardium of the heart.

28. A method for treating dysfunctional muscle tissue comprising:

providing therapeutic material configured to improve muscular function;

providing an angiogenic implant;

placing the implant in dysfunctional tissue; and

associating the therapeutic material with the angiogenic implant that has been placed in the tissue.

29. A method of treating dysfunctional muscle tissue as defined in claim 28 wherein the tissue is myocardial tissue of the heart.

30. A method of treating dysfunctional muscle tissue as defined in claim 29 wherein the heart is accessed surgically and the implant is delivered through the epicardium of the heart.

31. A method of treating dysfunctional muscle tissue as defined in claim 29 wherein the heart is accessed percutaneously and the implant is delivered through the endocardium of the heart.

32. A method of sustaining transplanted cells and host tissue comprising:

placing a mechanical implant at the transplant site to promote localized angiogenesis in the tissue to supply blood to the cells.

33. A method of treating a tumor comprising:

providing a scaffold structure;

providing an inhibitor material configured to inhibit tumor growth; and

implanting the scaffold and the biological material in the tumor.